title: The literature on inhibitors: articles that influence my management of patients with hemophilia A and high-titer inhibitors.
abstract: High-titer inhibitors represent the greatest management challenge faced by clinicians who treat patients with hemophilia A, as bleeding episodes no longer respond to standard factor VIII replacement therapy. Over the last seven decades, major strides have been made in inhibitor treatment. This article focuses on the seminal clinical observations and studies that provided the foundation for these advances in hemophilia care.
authors.affiliation: Louisiana Center for Bleeding and Clotting Disorders, Tulane University Medical Center, New Orleans, Louisiana 70112, USA. cleissi@tulane.edu
authors.forename: Cindy A
authors.initials: CA
authors.lastname: Leissinger
mesh_terms: D019774:Blood Coagulation Factor Inhibitors / Q000097:blood / Q000276:immunology; D003029:Coagulants / Q000097:blood / Q000276:immunology / Q000627:therapeutic use; D005169:Factor VIII / Q000276:immunology / Q000378:metabolism / Q000627:therapeutic use; D005260:Female; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy / Q000276:immunology; D006470:Hemorrhage / Q000097:blood / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D008297:Male
chemical_list: D019774:Blood Coagulation Factor Inhibitors; D003029:Coagulants; D005169:Factor VIII